Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics

Figure 1

A diagram summarizing criteria for decision making of go or no-go for each step at discovery and preclinical phases of AL development. The right column is set of criteria during each step (IC₅₀ is concentration that inhibits cell growth by 50%; MTD is maximum tolerated dose; NOAEL is no observed adverse effect level; MRSD is maximum recommended starting dose).